Novartis combination targeted therapy receives FDA approval
The FDA has approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) to treat patients with metastatic non-small cell lung cancer.
List view / Grid view
News
Study predicts 1.2 million people in UK will be living with dementia by 2040
By 2040, there will be over 1.2 million people living with dementia in England and Wales (an increase of 57% from 2016), due to increased life expectancy...
Wickham Laboratories now offering full suite of medical device biocompatibility and safety testing
Wickham Laboratories is pleased to announce the extension of its medical device testing services...
Heart failure market worth $16 billion by 2026 as Novartis’ drug triggers growth
The heart failure space across the seven key markets of the US, France, Germany, Italy, Spain, the UK and Japan is set to grow from $3.7 billion in 2016 to around $16.1 billion by 2026, representing an impressive compound annual growth rate of 15.7%, according to research and consulting firm…
Patheon to invest $45 million in spray drying & manufacturing solutions
Patheon expects to invest approximately $45 million at key sites across its network in spray drying capabilities and flexible manufacturing solutions...
ABPI respond to statement of UK Government’s medicines regulation plans
The ABPI has responded to a joint letter from Jeremy Hunt, Secretary of State for Health, and Greg Clark, Secretary of State for Business, published by the Financial Times, that outlined the UK Government’s plans for the regulation of medicines as the UK leaves the European Union (EU).
NICE recommends Lilly’s Baricitinib (Olumiant) to treat rheumatoid arthritis
Baricitinib is the first JAK inhibitor to be recommended by NICE to treat rheumatoid arthritis in adults who have not responded to conventional therapy…
Sandoz receives EU approval in Europe for Rixathon (biosimilar rituximab)
The EC has approved Sandoz’ Rixathon (biosimilar rituximab) for use in Europe. Rixathon is approved for use in all indications of the reference medicine...
NICE approves AstraZeneca’s COPD drug
The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending roflumilast (Daxas, AstraZeneca) for chronic obstructive pulmonary disease (COPD).
Steven Baertschi joins EPR advisory board
Dr Steven Baertschi has joined the editorial advisory board of European Pharmaceutical Review.
Fujifilm Diosynth Biotechnologies announce successful completion of its 100th paveway
Fujifilm Diosynth Biotechnologies has announced the successful completion of its 100th program using its pAVEway™ Advanced Protein Expression system...
62% of medicines dispensed in Europe are generic, says new IMS data
New IMS data reveals the growing importance of generic medicines for public health as they now account for 62% of medicines dispensed in Europe delivering huge value while impacting only 4% of total healthcare budgets.
Metrohm & CAMO Software are announcing a global partnership
Optimising analysis in the laboratory with modern instruments and high-performance software...
Sandoz receives EU approval for Erelzi (biosimilar etanercept)
The European Commission (EC) has approved Sandoz’ (a Novartis division) Erelzi (biosimilar etanercept) for use in Europe, to treat inflammatory diseases...
DiaSorin and Tecan to collaborate in new platform development
DiaSorin and Tecan Group have announced that they have agreed to collaborate in a development under which DiaSorin will make use of Tecan’s Fluent® Laboratory Automation Solution as its nucleic acid extraction platform...
